Bitte beachten Sie, dieser Teil unserer Webseite ist nur auf Englisch verfügbar
Low dose acetylsalicylic acid (ASA) is widely used and up to 50% of everyday users experience side effects
American associations ACC/AHA1 as well as European associations2 recommend daily use of low dose ASA for primary prevention of cardiovascular issues.
ASA users are aware of potential gastrointestinal side effects
51% of consumers are either concerned or have experienced side effects from everyday ASA use. Upset stomach is the most experienced side effect, whereas gastrointestinal ulcers raise the most concern.5
Our unique product – Bif195
As a result of an intense pre-clinical screening program, including state of the art in vitro and in vivo models, Chr. Hansen’s research team identified Bif195 as a promising new candidate to support intestinal tissue health alongside daily low dose ASA usage in healthy volunteers*.
In a golden standard clinical trial published in Gastroenterology 2019, Chr. Hansen’s unique probiotic strain, Bif195, was demonstrated to help protect against small-intestinal damage caused by ASA in healthy volunteers.6